DE60229779D1 - Langkettige fettalkoholsubstituenten in mitteln gegen krebs - Google Patents

Langkettige fettalkoholsubstituenten in mitteln gegen krebs

Info

Publication number
DE60229779D1
DE60229779D1 DE60229779T DE60229779T DE60229779D1 DE 60229779 D1 DE60229779 D1 DE 60229779D1 DE 60229779 T DE60229779 T DE 60229779T DE 60229779 T DE60229779 T DE 60229779T DE 60229779 D1 DE60229779 D1 DE 60229779D1
Authority
DE
Germany
Prior art keywords
omega
subsidies
long
against cancer
agents against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229779T
Other languages
English (en)
Inventor
Hans Rudolf Pfaendler
Alexander Klingl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60229779D1 publication Critical patent/DE60229779D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60229779T 2001-12-31 2002-12-30 Langkettige fettalkoholsubstituenten in mitteln gegen krebs Expired - Lifetime DE60229779D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01131049 2001-12-31
PCT/EP2002/014809 WO2003055864A1 (en) 2001-12-31 2002-12-30 Long chain fatty alcohol substituents in antineoplastic agents

Publications (1)

Publication Number Publication Date
DE60229779D1 true DE60229779D1 (de) 2008-12-18

Family

ID=8179720

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229779T Expired - Lifetime DE60229779D1 (de) 2001-12-31 2002-12-30 Langkettige fettalkoholsubstituenten in mitteln gegen krebs

Country Status (9)

Country Link
US (1) US20040266747A1 (de)
EP (1) EP1465876B1 (de)
JP (1) JP2005513156A (de)
AT (1) ATE413390T1 (de)
AU (1) AU2002367194B2 (de)
CA (1) CA2464937A1 (de)
DE (1) DE60229779D1 (de)
ES (1) ES2316651T3 (de)
WO (1) WO2003055864A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105153A1 (en) * 2004-04-30 2005-11-10 Kopran Research Laboratories Limited Hydroxyalkyl derivatives of biologically active compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH633280A5 (de) * 1978-03-09 1982-11-30 Elkawi Ag 5-fluoruracil-derivate und diese verbindungen enthaltende arzneimittel.
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
EP0167310B1 (de) * 1984-06-27 1991-05-29 Johnson Matthey Public Limited Company Platinkoordinationsverbindungen
DE3432320A1 (de) * 1984-09-03 1986-03-13 Behringwerke Ag, 3550 Marburg Cis-platin-komplexe mit einem pentaerythritderivat als liganden, verfahren zu ihrer herstellung und diese verbindungen enthaltendes pharmazeutisches mittel
GB9322795D0 (en) * 1993-11-05 1993-12-22 Wellcome Found Novel compounds
AU1608801A (en) * 1999-11-15 2001-05-30 Parker Hughes Institute Diamino platinum (ii) antitumor complexes

Also Published As

Publication number Publication date
AU2002367194B2 (en) 2008-10-30
WO2003055864A1 (en) 2003-07-10
EP1465876A1 (de) 2004-10-13
ATE413390T1 (de) 2008-11-15
CA2464937A1 (en) 2003-07-10
AU2002367194A1 (en) 2003-07-15
ES2316651T3 (es) 2009-04-16
EP1465876B1 (de) 2008-11-05
JP2005513156A (ja) 2005-05-12
US20040266747A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
KR960705810A (ko) 퀴나졸린 유도체(quinazoline derivatives)
MX2013002558A (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
BR0211332B1 (pt) composiÇço poliolefÍnica, processo para a preparaÇço de dita composiÇço, bem como artigo compreendendo a mesma.
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
EP1490371A4 (de) Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
PE20090678A1 (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
PT1044967E (pt) Inibidores da uroquinase do tipo 2-piridinilguanidina
AR069436A1 (es) Compuestos de piridina
PT1045021E (pt) Composicao que inclui uma mistura de mono- di- e trigliceridos alcoxilados e glicerina
TR200002237T2 (tr) Benzotiyadiazol ve türevleri
DE69825626D1 (de) Heterozyklische cytotoxische wirkstoffe
CY1111569T1 (el) Μονολυσινικα αλατα αζολικων ενωσεων
IL153352A0 (en) Coumarin derivatives with comt inhibiting activity
DE60229779D1 (de) Langkettige fettalkoholsubstituenten in mitteln gegen krebs
UY29801A1 (es) Derivados de quinazolina, sales farmacéuticamente aceptables de las mismas, composiciones farmacéuticas conteniéndolas, procedimientos de preparación y aplicaciones.
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
BR0108990A (pt) Processo para preparação de derivados de pirimidona com atividade antifungos
ATE517087T1 (de) Cbp-verbindung
CO5080802A1 (es) Nuevos compuestos heterociclicos inhibidores de la fosfodiesteresa iv y su formulacion y uso como productos farmaceuticos
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
AR050648A1 (es) Derivados de alcaloides cuaternarios, composiciones farmaceuticas que los contienen y su uso en el tratamiento de disfunciones metabolicas, inmunologicas y cancer
ATE371644T1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition